Profle of Xeomin®(incobotulinumtoxina) for the treatment of blepharospasm

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 725-732

  Park, Juwan ^a   Lee, Michael S ^b   Harrison, Andrew R ^c  

^a The Catholic University of Korea   (South Korea)

^b Neurology and Neurosurgery ^*  (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Blepharospasm; Botulinum neurotoxin type a; Complexing proteins; Incobotulinumtoxina; Neutralizing antibodies; Xeominspi_sup spii_sup

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; HEMAGGLUTININ; NEUROTOXIN; NEUTRALIZING ANTIBODY; PLACEBO;

ANTIBODY PRODUCTION; BIOEQUIVALENCE; BLEPHAROSPASM; CERVICAL DYSTONIA; CLOSTRIDIUM BOTULINUM; DOSE RESPONSE; DRUG ANTIGENICITY; DRUG DIFFUSION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; DRUG TREATMENT FAILURE; DRY EYE; FERMENTATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PROTEIN FUNCTION; PTOSIS; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SPASTICITY;

EID: 79958861460     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S13978     Document Type: Review

References (54)

1. Daniele Ranoux CG. Practical Handbook on Botulinum Toxin. Marseille: Solal Editeurs; 2007.
2. Dressler D. Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol. 2000;247(10):809-810.
3. Frueh BR, Felt DP, Wojno TH, Musch DC. Treatment of blepharospasm with botulinum toxin. A preliminary report. Arch Ophthalmol. 1984; 102(10):1464-1468.
4. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985;103(3): 347-350.
5. Jankovic J. Clinical efficacy and tolerability of Xeomin® in the treatment of blepharospasm. Eur J Neurol. 2009;16 Suppl 2:14-18.
6. Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN®) in focal dystonia. Drugs. 2007;67(5): 669-683.
7. Harrison AR. Chemodenervation for facial dystonias and wrinkles. Curr Opin Ophthalmol. 2003;14(5):241-245.
8. Dressler D. Botulinum toxin for treatment of dystonia. Eur J Neurol. 2010;17 Suppl 1:88-96.
9. Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med. 1993;86(8):493-494.
10. Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA. 2011;305(1):89-90.
11. ® is free from complexing proteins. Toxicon. 2009; 54(5):697-701.
12. Greene P, Fahn S, Diamond B. Development of resistance to botuli-num toxin type A in patients with torticollis. Mov Disord. 1994;9(2): 213-217.
13. Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113(3): 303-312.
14. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64(11):1949-1951.
15. Benecke R. Current status of the use of Botulinum neurotoxin type A. Eur J Neurol. 2009;16 Suppl 2:1.
16. Hasegawa K, Watanabe T, Suzuki T, et al. A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms. J Biol Chem. 2007;282(34):24777-24783.
17. ®. Mov Disord. 2008;23 Suppl 1:S20-S21.
18. Hambleton P. Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol. 1992;239(1):16-20.
19. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics. 2010;4:325-332.
20. Ohishi I, Sugii S, Sakaguchi G. Oral toxicities of Clostridium botulinum toxins in response to molecular size. Infect Immun. 1977; 16(1):107-109.
21. Chen F, Kuziemko GM, Stevens RC. Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect Immun. 1998;66(6):2420-2425.
22. Fujinaga Y. Transport of bacterial toxins into target cells: pathways followed by cholera toxin and botulinum progenitor toxin. J Biochem. 2006;140(2):155-160.
23. Jin Y, Takegahara Y, Sugawara Y, Matsumura T, Fujinaga Y. Disruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins - differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type C. Microbiology. 2009;155(Pt 1):35-45.
24. Johnson EA, Bradshaw M. Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon. 2001;39(11):1703-1722.
25. Blümel J. NT 201 - a new botulinum neurotoxin A. A preparation free of complexing proteins demonstrating the safety and beneft of decreased total clostidial protein burden. J Parkinsonism Relat Disord. 2005;11 Suppl 2:S267.
26. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol. 2006;13 Suppl 4:10-19.
27. De Almeida AT, De Boulle K. Diffusion characteristics of botulinum neu-rotoxin products and their clinical signifcance in cosmetic applications. J Cosmet Laser Ther. 2007;9 Suppl 1:17-22.
28. Pickett A, Dodd S, Rzany B. Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. J Cosmet Laser Ther. 2008;10(3): 181-183.
29. Dodd SL, Rowell BA, Vrabas IS, Arrowsmith RJ, Weatherill PJ. A comparison of the spread of three formulations of botulinum neu-rotoxin A as determined by effects on muscle function. Eur J Neurol. 1998;5(2):181-186.
30. Tang-Liu DD, Aoki KR, Dolly JO, et al. Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon. 2003;42(5):461-469.
31. Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blephar-ospasm. Mov Disord. 2009;24(3):407-413.
32. Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of NT 201 (Botulinum neurotoxin free from complexing proteins) in blepharospasm. Neurology. 2009;72 Suppl 3:Abstr 346.
33. Friday D, Bigalke H, Frevert J. In vitro stability of botulinum toxin complex at physiological pH and temparature. Naunyn Schmideberg's Arch Pharmacol. 2002;365 Suppl 2:Abstr 46.
34. Brin MF. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl. 1997;6:S208-S220.
35. ® is stable without refrigeration: Complexing proteins are not required for stability of botulinum toxin type A preparations. Toxicon. 2008;51:13, Abstr 36.
36. Frevert J. Xeomin: an innovative new botulinum toxin type A. Eur J Neurol. 2009;16 Suppl 2:11-13.
37. Lee JC, Yokota K, Arimitsu H, et al. Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology. 2005;151(Pt 11):3739-3747.
38. Atassi MZ. On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology. 2006;152(Pt 7): 1891-1895; discussion 1895-1897.
39. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immuno-genicity of original versus current botulinum toxin in cervical dystonia. Neurolog y. 2003;60(7):1186-1188.
40. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol. 2006;13 Suppl 4:35-40.
41. ®) in Cynomolgus monkeys following high-dose injections. Mov Disord. 2008;23 Suppl 1:S15.
42. Blümel J, Frevert J, Schwaier A. Comparative antigenicity of three preparations on botulinum neurotoxin A in the rabbit. Neurotox Res. 2006;9:238.
43. ®) provided sustained effcacy and was safe in spasticity: 89 weeks long-term data. J Neurol Sci. 2009;285 Suppl 1:S75-S76.
44. ®: Summary of product characteristics. Greensboro, NC: Merz Pharmaceuticals; 2010.
45. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761-1768.
46. Dressler D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur Neurol. 2002;48(1):26-29.
47. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurolog y. 1996;46(1):26-29.
48. ® in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64(1):6-12.
49. ®: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry. 2002;72(4):459-462.
50. ®: long term results. Eur J Neurol. 2009;16 Suppl 2:2-5.
51. ®. Toxicon. 2008;51 Suppl 1:10.
52. ® (incobotulinumA) injection [prescribing information]. Greensboro, NC: Merz Pharmaceuticals, LLC; 2010.
53. ®: Summary of product characteristics. Irvine, CA: Allergan Inc; 2010.
54. ®: Summary of product characteristics. Slough, UK: Ipsen Ltd; 2009.